Literature DB >> 16289915

An improved expression plasmid for affinity purification of Staphylococcus aureus gyrase A subunit.

Jacob Strahilevitz1, Yoshikuni Onodera, David C Hooper.   

Abstract

Of the bacterial topoisomerases, the gyrase A subunit (GyrA) of Staphylococcus aureus is particularly difficult to purify because of its tendency to form inclusion bodies. Previous attempts at purification yielded low concentrations of protein with reduced specific activity. To overcome this problem, we modified the commercially available plasmid expression vector, pBAD/Thio-TOPO, via the addition of DNA sequences encoding a hexahistidine tag upstream and a cleavage site for tobacco etch virus protease downstream of the gene encoding thioredoxin. The resulting expression system consisting of the modified plasmid, pSAGA7, and the recommended host strain, Escherichia coli TOP 10, facilitated high level expression of soluble GyrA and its affinity purification to over 95% homogeneity. Purified GyrA had high biological activity as evidenced by a specific activity of 4.3x10(5)U/mg. The pSAGA7/TOP10 expression system also facilitated the expression and purification of a subunit of S. aureus topoisomerase IV, ParE, and a recently discovered protein unrelated to topoisomerases, QnrB, two "hard to purify" proteins. We conclude that pSAGA7 might be useful for high-level soluble expression and purification of diverse microbial proteins.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16289915     DOI: 10.1016/j.pep.2005.08.009

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  5 in total

1.  Role of the extended alpha4 domain of Staphylococcus aureus gyrase A protein in determining low sensitivity to quinolones.

Authors:  Jacob Strahilevitz; Ari Robicsek; David C Hooper
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

2.  In vitro and in vivo profiles of ACH-702, an isothiazoloquinolone, against bacterial pathogens.

Authors:  Michael J Pucci; Steven D Podos; Jane A Thanassi; Melissa J Leggio; Barton J Bradbury; Milind Deshpande
Journal:  Antimicrob Agents Chemother       Date:  2011-04-04       Impact factor: 5.191

3.  In vitro antituberculosis activities of ACH-702, a novel isothiazoloquinolone, against quinolone-susceptible and quinolone-resistant isolates.

Authors:  Michael J Pucci; Maria Ackerman; Jane A Thanassi; Carolyn M Shoen; Michael H Cynamon
Journal:  Antimicrob Agents Chemother       Date:  2010-06-01       Impact factor: 5.191

4.  Mechanism of action of the antibiotic NXL101, a novel nonfluoroquinolone inhibitor of bacterial type II topoisomerases.

Authors:  Michael T Black; Thérèse Stachyra; Denis Platel; Anne-Marie Girard; Monique Claudon; Jean-Michel Bruneau; Christine Miossec
Journal:  Antimicrob Agents Chemother       Date:  2008-07-14       Impact factor: 5.191

5.  Dual targeting of DNA gyrase and topoisomerase IV: target interactions of heteroaryl isothiazolones in Staphylococcus aureus.

Authors:  Jijun Cheng; Jane A Thanassi; Christy L Thoma; Barton J Bradbury; Milind Deshpande; Michael J Pucci
Journal:  Antimicrob Agents Chemother       Date:  2007-05-14       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.